Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD3xBCMA-bsAb
- Development stage
- Preclinical
- Lead developer
- Protheragen
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
CD3xBCMA-bsAb is a preclinical-stage bispecific antibody (bsAb) developed by Protheragen for the treatment of multiple myeloma. As a T-cell engager, the molecule is designed to simultaneously bind to the B-cell maturation antigen (BCMA), which is highly and selectively expressed on malignant plasma cells, and the CD3 epsilon subunit of the T-cell receptor complex on cytotoxic T cells. By cross-linking these two targets, the antibody facilitates the formation of an immunological synapse, leading to T-cell activation and the subsequent directed lysis of BCMA-expressing myeloma cells via perforin- and granzyme-mediated pathways. This therapeutic strategy aims to harness the patient's own immune system to eliminate cancer cells, addressing the unmet need in relapsed or refractory multiple myeloma.
- Other names
- BCMAxCD3 bispecific antibodyBCMAxCD-3 bispecific antibodyBCMAxCD 3 bispecific antibodyanti-BCMA/CD3 bispecific antibody
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on CD3xBCMA-bsAb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD3xBCMA-bsAb.